Cover Image
市場調查報告書

藥物分析:Opdivo

Drug analysis: Opdivo

出版商 Datamonitor Healthcare 商品編碼 603944
出版日期 內容資訊 英文 103 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物分析:Opdivo Drug analysis: Opdivo
出版日期: 2017年12月11日 內容資訊: 英文 103 Pages
簡介

本報告提供免疫查核點抑制劑Opdivo的相關調查,提供主要國家/地區的銷售額實際成果與預測,就各疾病來看的藥物評估·SWOT分析,及藥物簡介等資訊。

  • 產品簡介
  • Opdivo:大腸癌 (CRC)
  • Opdivo:頭頸癌
  • Opdivo:肝癌 (HCC)
  • Opdivo:膀胱癌
  • Opdivo:神經膠質母細胞瘤 (GBM)
  • Opdivo:腎細胞癌 (RCC)
  • Opdivo:非小細胞肺癌 (NSCLC)
  • Opdivo:胃癌
  • Opdivo:黑色素瘤
目錄
Product Code: DMKC0093240

Drug Overview:

Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T cells. PD-1 and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and B7 family. The B7 family cell surface molecules and the cytotoxic T-lymphocyte antigen 4 family both regulate complex signaling pathways that affect T-cell activation, tolerance, and immunopathology. Blocking the interactions between PD-1 and its corresponding ligands prevents T-cell exhaustion in patients with cancer, allowing the T cells to combat the tumor via natural immune response mechanisms.

TABLE OF CONTENTS

  • Product Profiles
  • Opdivo : Colorectal cancer (CRC)
  • Opdivo : Head and neck cancer
  • Opdivo : Hepatocellular carcinoma (HCC)
  • Opdivo : Bladder cancer
  • Opdivo : Glioblastoma (GBM)
  • Opdivo : Renal cell cancer (RCC)
  • Opdivo : Non-small cell lung cancer (NSCLC)
  • Opdivo : Gastric cancer
  • Opdivo : Melanoma

LIST OF FIGURES

  • Figure 1: Opdivo for colorectal cancer - SWOT analysis
  • Figure 2: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • Figure 3: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • Figure 4: Opdivo sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 5: Opdivo for head and neck cancer - SWOT analysis
  • Figure 6: Datamonitor Healthcare's drug assessment summary of Opdivo for SCCHN
  • Figure 7: Datamonitor Healthcare's drug assessment summary of Opdivo for SCCHN
  • Figure 8: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 9: Opdivo for HCC - SWOT analysis
  • Figure 10: Datamonitor Healthcare's drug assessment summary of Opdivo for HCC
  • Figure 11: Datamonitor Healthcare's drug assessment summary of Opdivo for hepatocellular carcinoma
  • Figure 12: Opdivo for urothelial bladder cancer - SWOT analysis
  • Figure 13: Datamonitor Healthcare's drug assessment summary for Opdivo in urothelial bladder cancer
  • Figure 14: Datamonitor Healthcare's drug assessment summary for Opdivo in urothelial bladder cancer
  • Figure 15: Opdivo for glioblastoma - SWOT analysis
  • Figure 16: Datamonitor Healthcare's drug assessment summary for Opdivo in glioblastoma
  • Figure 17: Datamonitor Healthcare's drug assessment summary for Opdivo in glioblastoma
  • Figure 18: Opdivo pivotal trial data in renal cell cancer
  • Figure 19: Opdivo for renal cell cancer - SWOT analysis
  • Figure 20: Datamonitor Healthcare's drug assessment summary of Opdivo for renal cell cancer
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Opdivo for renal cell cancer
  • Figure 22: Opdivo for non-small cell lung cancer - SWOT analysis
  • Figure 23: Datamonitor Healthcare's drug assessment summary for Opdivo in non-small cell lung cancer
  • Figure 24: Datamonitor Healthcare's drug assessment summary for Opdivo in non-small cell lung cancer
  • Figure 25: Opdivo for gastric cancer - SWOT analysis
  • Figure 26: Datamonitor Healthcare's drug assessment summary for Opdivo in gastric cancer
  • Figure 27: Datamonitor Healthcare's drug assessment summary for Opdivo in gastric cancer
  • Figure 28: Opdivo in melanoma - SWOT analysis
  • Figure 29: Datamonitor Healthcare's drug assessment summary of Opdivo for melanoma
  • Figure 30: Datamonitor Healthcare's drug assessment summary of Opdivo for melanoma

LIST OF TABLES

  • Table 1: Opdivo drug profile
  • Table 2: Opdivo pivotal trial data in colorectal cancer
  • Table 3: Opdivo early-phase trials in colorectal cancer
  • Table 4: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • Table 5: Patients treated with Opdivo across the US and five major EU markets, by country, 2016-25
  • Table 6: Opdivo drug profile
  • Table 7: Opdivo pivotal trial data in head and neck cancer
  • Table 8: Opdivo ongoing late-phase trials in head and neck cancer
  • Table 9: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 10: Opdivo patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 11: Opdivo drug profile
  • Table 12: Opdivo Phase III trial in HCC
  • Table 13: Opdivo Phase I/II data in HCC
  • Table 14: Opdivo drug profile
  • Table 15: Opdivo pivotal trial data in urothelial bladder cancer
  • Table 16: Opdivo ongoing late-phase trials in urothelial bladder cancer
  • Table 17: Opdivo drug profile
  • Table 18: Opdivo Phase III data in glioblastoma
  • Table 19: Opdivo Phase III trials in glioblastoma
  • Table 20: Opdivo drug profile
  • Table 21: Opdivo ongoing Phase III clinical trial in renal cell cancer
  • Table 22: Opdivo drug profile
  • Table 23: Opdivo pivotal trial data in non-small cell lung cancer
  • Table 24: Opdivo ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 25: Opdivo drug profile
  • Table 26: Opdivo late-phase trial in gastric cancer
  • Table 27: Opdivo early-phase data in gastric cancer
  • Table 28: Opdivo drug profile
  • Table 29: Opdivo pivotal trial data in melanoma
  • Table 30: Opdivo late-phase clinical trial data in melanoma
  • Table 31: Opdivo ongoing late-phase clinical trials in melanoma
Back to Top